Open access
Oct 2026
A Multi-Biomarker Signature of Immune Activation and Metabolic Shift Predicts Treatment Success in Localized Prostate Cancer
A multi-biomarker panel, notably including SDF1, AD, and IL-39, emerges as a promising discovery-phase signature that, following independent external validation, may provide a non-invasive method for monitoring therapeutic response, but further validation is needed before clinical use.
AbdulQader M. AbdulQader, M. K. Abd, Kawthar Amer al-Shamari et al.
· Asian Pacific Journal of Can... · 0 citations